- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03914755
A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects
A Phase 1, Open Label, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib (ONT-380) in Healthy Japanese and Caucasian Subjects
This study is being done to compare the pharmacokinetics (PK) and safety/tolerability of tucatinib in healthy Japanese and Caucasian participants.
Three cohorts of healthy Japanese and Caucasian men and women will be admitted to the Clinical Research Unit (CRU) and receive multiple oral doses of tucatinib over 14 days with and without food.
Subjects will be in the study for up to 45 days, including the screening period.
Due to practical considerations, each cohort will be dosed sequentially (this is not a dose escalation study).
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Glendale, California, United States, 91206
- PAREXEL International, Early Phase Clinical Unit - Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index between 18 and 32 kg/m^2 and a total body weight between 50 and 100 kg
- In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiograms, vital signs measurements, or clinical laboratory evaluations
- Female subjects participating in the study will be of non-childbearing potential. Male subjects will be surgically sterile for at least 90 days or will agree to use contraception during the study and for 90 days after last dose of study drug.
Japanese subjects:
- Must have been born in Japan
- Must have 2 biological Japanese parents and 4 biological Japanese grandparents as confirmed by interview
- Must have spent less than 10 years outside of Japan, and has no significant changes in lifestyle, including diet, since leaving Japan
Exclusion Criteria:
- Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
- Current condition possibly affecting drug absorption
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
- History of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs
- History of alcoholism or drug/chemical abuse within 2 years of check-in
- History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects
- Positive hepatitis panel and/or positive human immunodeficiency (HIV) test
- Liver function tests, serum creatinine, hemoglobin, or hematocrit values outside of the normal reference range
- Single 12-lead ECG demonstrating QTcF>450 msec for males or >470 msec for females
- Participation in a clinical study involving administration of an investigational drug in the past 30 days from last dose or 5 half-lives (whichever is longer)
- Use of any products known to alter drug absorption, metabolism or elimination processes, including St. John's wort and known strong inhibitors or inducers of CYP3A4 or CYP2C8, within 30 days
- Use of or intention to use any prescription or nonprescription products, including vitamins, minerals and herbal preparations within 14 days
- Use of tobacco- or nicotine-containing products within 3 months
- Receipt of blood products within 2 months
- Donation of blood from 56 days before the Screening Visit, plasma from 2 weeks before the Screening Visit or platelets from 6 weeks before the Screening Visit
- Poor peripheral venous access
- Have previously completed or withdrawn from this study or any other study investigating tucatinib and have previously received the study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
50 mg twice daily on Days 1-13 and once daily on Day 14
|
Administered via oral tablet
|
Experimental: Cohort 2
150 mg twice daily on Days 1-13 and once daily on Day 14
|
Administered via oral tablet
|
Experimental: Cohort 3
300 mg twice daily on Days 1-13 and once daily on Day 14
|
Administered via oral tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed concentration (Cmax) of tucatinib
Time Frame: 14 days
|
14 days
|
Cmax of ONT-993
Time Frame: 14 days
|
14 days
|
Time of the maximum observed concentration (tmax) of tucatinib
Time Frame: 14 days
|
14 days
|
Tmax of ONT-993
Time Frame: 14 days
|
14 days
|
AUC from time 0 to the time of last quantifiable concentration (AUClast) of tucatinib
Time Frame: 14 days
|
14 days
|
AUClast of ONT-993
Time Frame: 14 days
|
14 days
|
AUC from time 0 to 12 hours postdose (AUC0-12hr) of tucatinib
Time Frame: 14 days
|
14 days
|
AUC0-12hr of ONT-993
Time Frame: 14 days
|
14 days
|
AUC from time 0 extrapolated to infinity (AUC0-inf) of tucatinib
Time Frame: 1 day
|
1 day
|
AUC from time 0 extrapolated to infinity (AUC0-inf) of ONT-993
Time Frame: 1 day
|
1 day
|
Percentage of AUC0-inf due to extrapolation (%AUCextrap) of tucatinib
Time Frame: 1 day
|
1 day
|
%AUCextrap of ONT-993
Time Frame: 1 day
|
1 day
|
Apparent total clearance (CL/F) of tucatinib
Time Frame: 14 days
|
14 days
|
Apparent volume of distribution during the terminal phase (Vz/F) of tucatinib
Time Frame: 14 days
|
14 days
|
Metabolite-to-parent molar ratio based on AUC (MRAUC) of ONT-993
Time Frame: 14 days
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events (AEs)
Time Frame: 17 days
|
17 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Joseph Woolery, PharmD, BCOP, Seagen Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SGNTUC-015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Tucatinib
-
Cascadian Therapeutics Inc.Completed
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
UNICANCERSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Leptomeningeal Disease | Leptomeningeal MetastasisFrance
-
Institut CurieSeagen Inc.RecruitingHER2-positive Breast CancerFrance
-
Seagen Inc.CompletedHER2 Positive Breast CancersUnited States, Canada
-
Seagen Inc.Active, not recruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States, Korea, Republic of, United Kingdom, Taiwan, Canada, Australia
-
Silverback TherapeuticsTerminatedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Colorectal Cancer | HER2-expressing Non-small Cell Lung CancerUnited States
-
Seagen Inc.CompletedHepatic ImpairmentUnited States
-
Seagen Inc.Active, not recruitingHER2 Positive Breast CancerUnited States
-
Seagen Inc.CompletedHER2 Positive Breast CancerUnited States, Spain, Belgium, Germany, Israel, France, United Kingdom, Austria, Denmark, Italy, Australia, Canada, Czechia, Portugal, Switzerland